KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $42.00

KalVista Pharmaceuticals (NASDAQ:KALV) had its price target lifted by Stifel Nicolaus from $39.00 to $42.00 in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other analysts also recently issued reports on the stock. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Citizens Jmp decreased their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Thursday. Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Needham & Company LLC upped their price objective on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.60.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $19.33 on Thursday. The business’s 50-day simple moving average is $16.04 and its 200 day simple moving average is $14.46. The company has a market cap of $990.08 million, a P/E ratio of -4.89 and a beta of -0.35. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals has a one year low of $9.23 and a one year high of $19.95.

Insider Activity at KalVista Pharmaceuticals

In other news, CFO Brian Piekos sold 1,767 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $27,512.19. Following the completion of the sale, the chief financial officer owned 13,762 shares of the company’s stock, valued at approximately $214,274.34. This trade represents a 11.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Nicole Sweeny sold 3,975 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $61,890.75. Following the completion of the sale, the insider owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. This trade represents a 7.80% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 248,009 shares of company stock worth $4,213,467. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP bought a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth about $782,000. Invesco Ltd. increased its holdings in KalVista Pharmaceuticals by 23.1% in the fourth quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock valued at $1,258,000 after buying an additional 14,621 shares during the last quarter. XTX Topco Ltd bought a new stake in KalVista Pharmaceuticals in the fourth quarter valued at about $428,000. Vestal Point Capital LP raised its stake in KalVista Pharmaceuticals by 152.0% during the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after buying an additional 1,140,000 shares in the last quarter. Finally, Virtus Investment Advisers LLC lifted its holdings in KalVista Pharmaceuticals by 364.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company’s stock worth $653,000 after buying an additional 31,721 shares during the last quarter.

More KalVista Pharmaceuticals News

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.